Navigation Links
Efforts to develop new drugs that hopefully will never be used

Concerns about terrorist attacks, the prospect of a rogue nation using nuclear weapons and the Fukushima power plant accident in Japan are fostering efforts to develop a new family of drugs that everyone hopes will never be used, according to an article in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Ann M. Thayer, C&EN senior correspondent, explains that the federal government has launched programs to develop medical countermeasures against nuclear threats. Radiation releases can happen under various circumstances, including failure of safety systems at commercial nuclear power plants and terrorist attacks. The article describes programs run by the U.S. Food & Drug Administration (FDA), the U.S. Department of Health and Human Services and the National Institutes of Health that support several small companies as they try to develop drugs to treat acute radiation syndrome (ARS).

The article discusses the companies' approaches. Some seek to adapt existing drugs, including treatments for the side effects of radiation therapy for cancer. Thayer notes that because these drugs are already approved by the FDA, stockpiling them would be easier. Others are looking for new compounds that can treat the symptoms of ARS or remove radioactive particles from the body.


Contact: Michael Bernstein
American Chemical Society

Page: 1

Related biology news :

1. UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed
2. Report details efforts to improve, advance indoor microbial sampling
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. Artificial womb unlocks secrets of early embryo development
5. REST is crucial for the timing of brain development
6. Embryonic development protein active in cancer growth
7. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
8. Mini-CT scanner developed as a teaching tool
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Oceanographers develop method for measuring the pace of life in deep sediments
11. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
Post Your Comments:
(Date:10/8/2015)... Calif. , Oct. 8, 2015 ... of human interface solutions, announced today that it ... of fiscal 2016 on Thursday, October 22, 2015, ... host a corresponding conference call for analysts and ... during which management may discuss forward-looking information.    ...
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/6/2015)... , Oct. 6, 2015  Maverix Biomics, Inc., ... enhancements to its software portfolio with the debut ... for differential expression in eukaryotes. The software is ... a cloud-based genomic analysis solution that leverages proven ... from next-generation sequencing efforts. Garry Nolan,s ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... 2015 PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed ... at near average with 1,308,352 shares being traded. PMCB shares ... hitting a low of $.072 in September, then bouncing back ... Our due diligence will show investors in PharmaCyte Biotech, ... report by using the link below at no cost. ...
(Date:10/13/2015)... , October 13, 2015 " Microbiology ... Forecast 2015 - 2023 " , the global ... is anticipated to reach US$7.59 bn by 2023, expanding at a ... --> " Microbiology Culture Market - Global Industry ... " , the global microbiology culture market was valued ...
(Date:10/13/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting company at the Dawson James Small Cap ... Jupiter, Florida on October 15, ... clinical-stage immunotherapy company specializing in the development of innovative ...
(Date:10/13/2015)... Charlotte, NC (PRWEB) , ... October 13, 2015 ... ... high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo ... 450 in the U.S. for the ablation of prostate tissue. Sonablate® is ...
Breaking Biology Technology: